Watch Ticker

argenx SE American Depositary Shares

Go to argenx SE American Depositary Shares Website

$674.90

-15.42 (-2.23%)

Live

Previous Close

$674.9

Day Range

$674.84 - $696.205

Previous Day Range

$673.57 - $691.02

Market Cap

$42.2 billion USD

Day Vol.

476276

Previous Day Vol.

410973

Currency

USD

Primary Exchange

Nasdaq

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized mya...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Custom Market Insights - [Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global Ultomiris drug market is expected to grow from USD 4.16 Billion in 2024 to USD 64.12 Billion by 2034, with a robust 31.52% CAGR, driven by increasing demand for long-acting treatments for rare disorders like PNH and gMG.

Related tickers: AZN, XNCR, ARGX.

Read Full Article

Argenx Se - argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes

argenx announced positive Phase 1b study results for ARGX-119, a first-in-class antibody targeting muscle-specific kinase (MuSK) in congenital myasthenic syndromes, demonstrating favorable safety and consistent functional improvements.

Related tickers: ARGX.

Read Full Article

Trending Tickers

Please sign in to view